SCHEDULE 13G/A: EcoR1 Capital Reduces Stake in Aligos Therapeutics Below 5%

EcoR1 Capital, LLC and its affiliates have filed an amended Schedule 13G, disclosing a reduction in their beneficial ownership of Aligos Therapeutics, Inc. common stock to 3.9% as of March 31, 2025.

Summary

• EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. are the reporting persons.
• As of March 31, 2025, EcoR1 Capital, LLC and Oleg Nodelman beneficially own an aggregate of 210,634 shares of Aligos Therapeutics, Inc. Common Stock, representing 3.9% of the class.
• This ownership includes 88,569 shares of Common Stock and 122,065 shares underlying warrants, which are subject to a 9.99% beneficial ownership limitation.
• EcoR1 Capital Fund Qualified, L.P. beneficially owns 199,036 shares, representing 3.7% of the class, comprising 83,807 shares of Common Stock and 115,229 shares underlying warrants.
• The percentage ownership is calculated based on 5,314,311 shares of voting Common Stock outstanding on March 6, 2025, as reported in Aligos Therapeutics' Form 10-K for the fiscal year ended December 31, 2024.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual, regulatory filing disclosing a change in beneficial ownership. It contains no subjective language or information that would indicate a positive or negative sentiment regarding the issuer's performance or prospects.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a routine disclosure of an institutional investor's stake falling below a reporting threshold and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's reduced stake, which may be noted by other investors but is unlikely to have a major direct impact given the passive nature of the investment.

Key Dates

Keywords

Aligos Therapeutics, EcoR1 Capital, Oleg Nodelman, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Biotechnology, Pharmaceuticals